Mexico

Mexico matters for psychedelic medicine in two different ways. It has deep Indigenous and cultural significance around psilocybin mushrooms and peyote, especially in Oaxaca and Wixarika sacred geographies.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Mexico.

1
Mexico is culturally central to psychedelic history, but formal medical access is still led by ketamine and esketamine.
2
Classical psychedelics are not merely grey-zone substances: the main compounds relevant to psychedelic medicine are Group I psychotropics and research-limited.
3
Esketamine has public-system formulary recognition through the Compendio, but real access still depends on institutional adoption, procurement and care setting.
4
Ketamine is a controlled medicine with recognised therapeutic use, but depression treatment remains off-label.
5
Mexico City is the formal research and regulatory node; Baja California is the most visible private ibogaine and cross-border treatment cluster.
6
Private ibogaine and 5-MeO-DMT services should be labelled as private, observational or unapproved activity, not as national medical access.

Research Snapshot

Blossom currently tracks 10 psychedelic clinical trials connected to Mexico.

Active trials: 0
Total trials: 10
Stakeholders: 48
Events: 0

Top Compounds

Ketamine(5)
Esketamine(4)

Medical Access Snapshot

Mexico remains restrictive for classical psychedelics, with psilocybin, LSD, MDMA, DMT and mescaline or peyote treated as Group I psychotropics and limited to authorised scientific research. Esketamine has public-system formulary recognition in the national Compendio, but real access depends on institutional adoption and procurement. Ketamine has controlled medical use, while depression treatment is off-label.

View trials→View stakeholders→Open access guide→

Regulatory Status

Mexico treats most classical psychedelics as tightly controlled Group I psychotropics under Article 245 of the General Health Law. Psilocin, psilocybin, hallucinogenic mushrooms, LSD, DMT, MDMA and mescaline or peyote sit in that high-control category, and Article 249 limits Group I acquisition to scientific research authorised by the health authority. Ketamine is different: it is a Group III controlled psychotropic with recognised therapeutic use, which supports ordinary controlled medical use while leaving depression treatment off-label. Esketamine now has public-system formulary recognition in the Compendio Nacional de Insumos para la Salud, but that does not prove uniform national access or reimbursement. Ibogaine and 5-MeO-DMT should be framed as unapproved private or research-adjacent activity, not as authorised medicines.

History of Research in Mexico

Mexico has one of the most important long-run psychedelic histories in the world. Indigenous mushroom and peyote practices predate modern clinical research, and current scholarship still documents Mazatec psilocybin mushroom veladas as living healing practices rather than historical curiosities. # #

International attention intensified after mid-twentieth-century reporting around Mazatec mushroom ceremonies and Maria Sabina. That visibility did not create the practice, but it did help bring Mexican psilocybin traditions into global scientific and cultural discussion. # #

Modern law then took a conservative shape. Mexico's General Health Law now places psilocybin, psilocin, hallucinogenic mushrooms, LSD, DMT, MDMA and mescaline or peyote in Group I, with acquisition limited to authorised scientific research. The result is not legal liberalisation, but a layered system of prohibition, cultural continuity, research permissions and uneven private practice. #

Recent policy has strengthened Indigenous sacred-site recognition rather than medical access. Mexico's 2023 sacred-sites decree and UNESCO's 2025 inscription of the Wixarika Route through Sacred Sites to Wirikuta matter for peyote, territorial governance and ecosystem mapping, but they are not psychedelic-medicine reforms. # #

Mexico City and Baja California

Mexico City is the main formal-sector node. COFEPRIS is based there, and the most visible domestic ketamine study links IMSS, the National Psychiatry Institute, ISSSTE and the National Geriatrics Institute. This is where regulation, public psychiatry and health research most clearly intersect. # #

Baja California, especially the Tijuana corridor, is the most visible private ibogaine and cross-border treatment cluster. It matters commercially and sociologically, but its evidence base is mostly observational and clinic-based rather than regulator-led. # #

Oaxaca and the Mazateca are essential for history and cultural context. They should not be reduced to a modern retreat market or presented as a clinical-trial hub. Ceremonial knowledge belongs in the cultural and historical part of the page, not in the medical-authorisation column. # #

Wirikuta and the wider Wixarika sacred-route geography are similarly important for peyote. The 2023 decree and 2025 UNESCO inscription reinforce that mescaline discussion in Mexico must account for Indigenous governance, ecology and sacred sites rather than treating peyote as a generic resource. # #

Research Focus

The clearest formal clinical-research footprint is esketamine. Mexican sites participated in Janssen treatment-resistant depression and long-term safety programmes, including TRANSFORM and SUSTAIN studies. Those programmes produced international peer-reviewed evidence, but they are multinational esketamine development studies rather than Mexican classical-psychedelic access programmes. # # #

A smaller domestic ketamine signal is also visible. NCT03473431 studied a single ketamine infusion for depressive symptoms in older adults undergoing ophthalmological surgery, with links to IMSS, the National Psychiatry Institute, ISSSTE and the National Geriatrics Institute in Mexico City. The published study reported short-term symptom improvement, but it does not establish an approved psychiatric ketamine label. # #

Outside orthodox trial infrastructure, Mexico-linked publications include observational work on ibogaine and sequential ibogaine plus 5-MeO-DMT programmes. These papers are relevant to the international evidence base, but most come from private, naturalistic or open-label treatment settings rather than pivotal regulatory trials. # #

I did not identify a strong public registry pipeline in Mexico for psilocybin, MDMA, LSD or DMT-assisted psychiatry by 13 May 2026. That absence should be read as a source boundary rather than proof that no academic interest exists, and registry searches should be repeated before publication. # #

Key Milestones

1957

Mazatec mushroom ceremonies associated with Maria Sabina become internationally visible, shaping global interest in psilocybin mushrooms.

1987

Reforms to the General Health Law establish the modern psychotropic-control architecture that still governs Group I substances and authorised research acquisition.

2013

NOM-012-SSA3-2012 enters into force, setting formal rules for health research in humans in Mexico.

2019

International esketamine phase 3 results begin publishing from programmes in which Mexican sites participated.

2022

The Mexican ketamine ophthalmological surgery study is published, linking IMSS, the National Psychiatry Institute, ISSSTE and the National Geriatrics Institute.

9 Aug 2023

Mexico publishes a decree recognising and protecting Indigenous sacred sites and pilgrimage routes relevant to peyote and Wixarika governance.

31 Oct 2023

Esketamine is added to the Compendio Nacional de Insumos para la Salud.

24 Mar 2025

Mexico publishes criteria for faster authorisation of human research protocols already authorised by certain foreign regulators.

17 Jul 2025

UNESCO inscribes the Wixarika Route through Sacred Sites to Wirikuta on the World Heritage List.

Future Outlook

The most likely near-term change is operational rather than legal. COFEPRIS reliance criteria for human research protocols could improve trial start-up for studies already cleared by certain foreign regulators, but that does not liberalise patient access by itself. # #

Esketamine is the main access variable to watch. The Compendio gives it public-system legitimacy and procurement potential, but the practical questions are centre adoption, budgets, referral rules and actual administration capacity. # #

For classical psychedelics, a broad national shift still looks unlikely in the next 12 to 24 months on the public sources reviewed. Movement is more likely through academic protocols, ethics approvals, foreign-sponsored trials and clearer professional standards than through general authorisation of psilocybin, MDMA, LSD or DMT medicines. # #